Who will pay for your product during NPS/EAP phase ?

Usually, hospitals and/or national insurance, or insurances systems bear the costs of Named Patient Sales in  most countries (France, Italy, Turkey, Switzerland  and Spain). 

It is important to consider  that if your drug is charged,  your EAP price might be used as a benchmark for pricing and reimbursement committees in Europe.

For more info, please contact useap@carthagenetics.com

 

 

Leave a Reply